[ Ссылка ]
Pharma is clearly worried about how the UK's exit from the EU will disrupt both the EMA's capacity for drugs reviews and the pan-European regulatory environment. Former EMA executive director Thomas Lönngren explained to Scrip during the BIO-Europe Spring meeting that the relationship between EMA and FDA could be a model the UK's MHRA could adopt if the British take a hard Brexit route.
